Literature DB >> 17192667

Allosteric modulators and selective agonists of muscarinic receptors.

Ulrike Holzgrabe1, Marco De Amici, Klaus Mohr.   

Abstract

Allosteric modulators of ligand-receptor interactions are found for a variety of receptors (Christopoulos, 2002). Allosteric agents attach to a binding site being topographically distinct from the site for conventional (orthosteric) agonists or antagonists. In the case of the muscarinic receptor, a huge selection of structurally divergent modulators has been described for different receptor subtypes (Mohr et al., 2003). Alkane-bisammonio-type compounds carrying lateral phthalimido substituents are known to have a high affinity for the common allosteric binding site of the muscarinic acetylcholine M2 receptor (mAChR M2), which is already occupied by the orthosteric antagonist N-methylscopolamine (NMS). The resulting allosteric inhibition of the dissociation of [3H]NMS from the M2 receptors in porcine cardiac homogenates served to indicate binding of the test compounds to the allosteric site. Additionally, allosteric modulators can strongly influence equilibrium binding of the orthosteric ligand: Its binding can be reduced, left unaltered or elevated, and encoded as negative, neutral, and positive cooperativity, respectively (Christopoulos and Kenakin, 2002). The cooperativity is strongly dependent on the pair of allosteric/orthosteric ligands and on the receptor subtype.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17192667     DOI: 10.1385/JMN:30:1:165

Source DB:  PubMed          Journal:  J Mol Neurosci        ISSN: 0895-8696            Impact factor:   3.444


  9 in total

1.  Synthesis and functional characterization of novel derivatives related to oxotremorine and oxotremorine-M.

Authors:  C Dallanoce; P Conti; M De Amici; C De Micheli; E Barocelli; M Chiavarini; V Ballabeni; S Bertoni; M Impicciatore
Journal:  Bioorg Med Chem       Date:  1999-08       Impact factor: 3.641

Review 2.  G protein-coupled receptor allosterism and complexing.

Authors:  Arthur Christopoulos; Terry Kenakin
Journal:  Pharmacol Rev       Date:  2002-06       Impact factor: 25.468

3.  New analogues of oxotremorine and oxotremorine-M: estimation of their in vitro affinity and efficacy at muscarinic receptor subtypes.

Authors:  E Barocelli; V Ballabeni; S Bertoni; C Dallanoce; M De Amici; C De Micheli; M Impicciatore
Journal:  Life Sci       Date:  2000-06-30       Impact factor: 5.037

Review 4.  Structure/activity relationships of M2 muscarinic allosteric modulators.

Authors:  K Mohr; C Tränkle; U Holzgrabe
Journal:  Receptors Channels       Date:  2003

Review 5.  Allosteric binding sites on cell-surface receptors: novel targets for drug discovery.

Authors:  Arthur Christopoulos
Journal:  Nat Rev Drug Discov       Date:  2002-03       Impact factor: 84.694

6.  Development of a new type of allosteric modulator of muscarinic receptors: hybrids of the antagonist AF-DX 384 and the hexamethonio derivative W84.

Authors:  Marion Mohr; Eberhard Heller; Ameneh Ataie; Klaus Mohr; Ulrike Holzgrabe
Journal:  J Med Chem       Date:  2004-06-03       Impact factor: 7.446

7.  Design, synthesis, and action of oxotremorine-related hybrid-type allosteric modulators of muscarinic acetylcholine receptors.

Authors:  Teresa Disingrini; Mathias Muth; Clelia Dallanoce; Elisabetta Barocelli; Simona Bertoni; Kerstin Kellershohn; Klaus Mohr; Marco De Amici; Ulrike Holzgrabe
Journal:  J Med Chem       Date:  2006-01-12       Impact factor: 7.446

8.  Systematic development of high affinity bis(ammonio)alkane-type allosteric enhancers of muscarinic ligand binding.

Authors:  Mathias Muth; Wiebke Bender; Olaf Scharfenstein; Ulrike Holzgrabe; Edith Balatkova; Christian Tränkle; Klaus Mohr
Journal:  J Med Chem       Date:  2003-03-13       Impact factor: 7.446

9.  Muscarinic allosteric enhancers of ligand binding: pivotal pharmacophoric elements in hexamethonio-type agents.

Authors:  Mathias Muth; Matthias Sennwitz; Klaus Mohr; Ulrike Holzgrabe
Journal:  J Med Chem       Date:  2005-03-24       Impact factor: 7.446

  9 in total
  4 in total

1.  In vivo investigations on the cholinesterase-inhibiting effects of tricyclic quinazolinimines: scopolamine-induced cognitive impairments in rats are attenuated at low dosage and reinforced at higher dosage.

Authors:  D Appenroth; M Decker; C Tränkle; K Mohr; J Lehmann; C Fleck
Journal:  Pflugers Arch       Date:  2007-08-24       Impact factor: 3.657

2.  Bitopic ligands: all-in-one orthosteric and allosteric.

Authors:  Maud Kamal; Ralf Jockers
Journal:  F1000 Biol Rep       Date:  2009-10-14

Review 3.  Allosteric Modulation of Class A GPCRs: Targets, Agents, and Emerging Concepts.

Authors:  Eric A Wold; Jianping Chen; Kathryn A Cunningham; Jia Zhou
Journal:  J Med Chem       Date:  2018-08-28       Impact factor: 7.446

4.  Heterodimerization of Dibenzodiazepinone-Type Muscarinic Acetylcholine Receptor Ligands Leads to Increased M2R Affinity and Selectivity.

Authors:  Xueke She; Andrea Pegoli; Judith Mayr; Harald Hübner; Günther Bernhardt; Peter Gmeiner; Max Keller
Journal:  ACS Omega       Date:  2017-10-16
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.